SPD 451

Drug Profile

SPD 451

Alternative Names: Dopamine D1 agonists - Shire Pharmaceuticals; SPD451

Latest Information Update: 17 Jun 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CeNeS Pharmaceuticals
  • Developer CeNeS Pharmaceuticals; Shire Pharmaceutical Development
  • Class
  • Mechanism of Action Dopamine D1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 17 Jun 2004 Discontinued - Preclinical for Parkinson's disease in United Kingdom (unspecified route)
  • 25 Jun 2002 This compound is still in active development with Shire Pharmaceuticals
  • 03 Jan 2001 Shire Pharmaceuticals has entered into a licensing agreement with CeNes for the dopamine D1 agonist programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top